Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

PHASE3CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

February 6, 2018

Primary Completion Date

April 10, 2019

Study Completion Date

April 6, 2022

Conditions
Hereditary AngioedemaHAE
Interventions
DRUG

BCX7353 capsules

BCX7353 oral capsules administered once daily

DRUG

Placebo oral capsule

Matching oral capsules administered once daily

Trial Locations (47)

1000

Study Center, Skopje

1090

Study Center, Vienna

10029

Study Center, New York

10117

Study Center, Berlin

17033

Study Center, Hershey

20815

Study center, Chevy Chase

27705

Study Center, Durham

28046

Study Center, Madrid

28277

Study Site, Charlotte

30460

Study Center, Pilsen

33613

Study Center, Tampa

35209

Study center, Birmingham

38043

Study Center, Grenoble

41013

Study Center, Seville

43235

Study center, Columbus

45231

Study Center, Cincinnati

48106

Study Center, Ann Arbor

55446

Study center, Plymouth

63141

Study Center, St Louis

72205

Study center, Little Rock

75012

Study Center, Paris

75231

Study center, Dallas

78229

Study Center, San Antonio

78731

Study center, Austin

80907

Study center, Colorado Springs

85251

Study center, Scottsdale

90404

Study center, Santa Monica

92122

Study Center, San Diego

94598

Study Center, Walnut Creek

97015

Study center, Clackamas

99202

Study Center, Spokane

547530

Study Center, Sângeorgiu de Mureș

02114

Study Center, Boston

07109

Study center, Belleville

07410

Study Center, Fair Lawn

08854

Study center, Piscataway

K1G 6C6

Study Center, Ottawa

M4V 1R2

Study Center, Toronto

G1V 4W2

Study Center, Québec

656 91

Study Center, Brno

D-60590

Study Center, Frankfurt

H-1225

Study Center, Budapest

08907

Study Center, Barcelona

CB2 0QQ

Study Center, Cambridge

GU16 7UJ

Study Center, Frimley

E1 2ES

Study Center, London

PL6 8DH

Study Center, Plymouth

Sponsors
All Listed Sponsors
lead

BioCryst Pharmaceuticals

INDUSTRY